Stock News and Filings Feed


Add MDXH
to your dashboard

ConfirmMDx Study Provides Further Validation Of Epigenetic Risk Profile

2017-08-10 devicespace
IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, August 10, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced that results from a study published in The Prostate further validated ConfirmMDx® for Prostate Cancer and showed that the test can provide treating urologists with deeper insights into a patient's risk for aggressive prostate cancer. The ConfirmMDx clinical model combines standard clinical risk factors with DNA-methylation intensity of GSTP1, APC and RASSF1 genes to improve patient risk stratification and guide repeat prostate biopsy decisions.

MVZ Dr. Stein & Kollegen First German Medical Laboratory To Offer The SelectMDx For Prostate Cancer Test

2017-07-31 devicespace
IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST- July 31, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced that MVZ Dr. Stein & Kollegen medical laboratory has signed an agreement to become the first German laboratory to offer the SelectMDx for Prostate Cancer test.

MDxHealth, Inc. Release: First German Medical Laboratory To Offer The SelectMDx For Prostate Cancer Test

2017-07-31 devicespace
IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST- July 31, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced that MVZ Dr. Stein & Kollegen medical laboratory has signed an agreement to become the first German laboratory to offer the SelectMDx for Prostate Cancer test.

MDxHealth, Inc. Release: SelectMDx To Be Distributed Across Middle East By

2017-07-10 devicespace
HERSTAL, BELGIUM - July 10, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced that it has signed a commercial agreement with IPS Genomix for the distribution of its SelectMDx® for Prostate Cancer test in the Middle East. With their expert teams covering Lebanon, Egypt, United Arab Emirates, Saudi Arabia, Oman, Bahrain, Qatar, and Jordan, IPS Genomix is ideally positioned to reach the estimated 1 million men across the region with an elevated PSA, who would be potential candidates for SelectMDx.

MDxHealth, Inc. Launches AssureMDx For Bladder Cancer Liquid Biopsy Test

2017-07-06 devicespace
NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, July 6, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced the commercial launch of its AssureMDx(TM) for Bladder Cancer test in the United States as a laboratory developed test (LDT). Testing will be conducted at the Company's state-of-the-art CAP and CLIA accredited laboratory facilities in Irvine, California.

MDxHealth, Inc. Launches Assuremdx For Bladder Cancer Liquid Biopsy Test

2017-07-06 devicespace
NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, July 6, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced the commercial launch of its AssureMDx(TM) for Bladder Cancer test in the United States as a laboratory developed test (LDT). Testing will be conducted at the Company's state-of-the-art CAP and CLIA accredited laboratory facilities in Irvine, California.

MDxHealth, Inc. And Collaborate On Oral Cancer Liquid Biopsy Test

2017-06-19 devicespace
NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, June 19, 2017 - MDxHealth SA (Euronext: MDXH.BR), today announced that it has signed a scientific agreement with QUT bluebox, the commercialization arm of the Queensland University of Technology (QUT), to develop a liquid biopsy epigenetic assay for the early detection of oral cancer.

MDxHealth, Inc. Release: Extrodinary General Shareholders' Meeting

2017-06-19 devicespace
IRVINE, CA, and HERSTAL, BELGIUM - 14:30 CEST, June 19 2017 - MDxHealth SA (Euronext: MDXH.BR) held today its Extraordinary General Shareholders' Meeting in Brussels. The shareholders approved all agenda items of the Extraordinary General Shareholders' Meeting.

MDxHealth, Inc. And Queensland University of Technology Collaborate On Oral Cancer Liquid Biopsy Test

2017-06-19 devicespace
Oral cancer has a significant global incidence with approximately over 20,000 cases diagnosed annually in the US alone. Early detection is key to survival, but noticeable symptoms appear at a more advanced stage when there is a less favorable prognosis. Currently, there are no US screening guidelines for head and neck cancers or proven blood or saliva-based diagnostic tests.

MDxHealth, Inc. Launches CE-Marked SelectMDx IVD PCR Kit And UrNCollect Device

2017-06-08 devicespace
The IVD PCR kit will enable diagnostic laboratories with manual and automated RNA extraction and PCR platforms to perform the SelectMDx liquid biopsy test in their own facility. The CE-marked UrNCollect device is a unique, user-friendly and compact collection tool that complements the IVD kit by enabling easy and efficient sample collection.

MDxHealth, Inc. Shareholder Transparency Notification

2017-05-16 devicespace
Capfi Delen Asset Management informed MDxHealth on May 11, 2017 that, as of May 8, 2017, its participation in MDxHealth increased above the threshold of 3% of the outstanding shares. Capfi Delen Asset Management now owns 1,522,000 shares, i.e. 3.05 %, of the outstanding shares of MDxHealth. Capfi Delen Asset Management is a Belgian Management Company of UCITS. For further information, reference is made to the information published on MDxHealth's website (http://www.

MDxHealth, Inc. Release: SelectMDx For Prostate Cancer Guides Patient Selection For mpMRI

2017-05-15 devicespace
IRVINE, CA, and HERSTAL, BELGIUM - 15:30 CEST, May 13, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced results from a retrospective study that showed SelectMDx(TM) for Prostate Cancer, a liquid biopsy test, identified men at risk for clinically significant prostate cancer who would benefit from a multiparametric MRI (mpMRI) scan. The study findings were presented at the 2017 American Urological Association (AUA) Annual Meeting in Boston, Massachusetts in the US.

MDxHealth, Inc. Release: ConfirmMDx Improves Prostate Cancer Diagnosis In African American Men

2017-05-12 devicespace
IRVINE, CA, and HERSTAL, BELGIUM - 16:00 CEST, May 12, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced that results from a retrospective study demonstrated that its ConfirmMDx® for Prostate Cancer test improved the identification of African American men at risk for aggressive cancer missed by a prostate biopsy. The study findings were presented in a podium session at the 2017 American Urological Association (AUA) Annual Meeting in Boston, Massachusetts in the US.

MDxHealth, Inc. And Collaborate On Next Generation (Epi)Genetic Cancer Diagnostics

2017-05-05 devicespace
IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, May 5, 2017 - MDxHealth SA (Euronext: MDXH.BR), today announced that it has signed an agreement with the Faculty of Health, Medicine and Life Sciences / School for Oncology and Developmental Biology (GROW) at Maastricht University to expand its existing research collaboration to develop commercial next generation (epi)genetic cancer diagnostics.

MDxHealth, Inc. And EXACT Sciences Sign Collaboration Agreement

2017-04-27 devicespace
IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, April 27, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced that it has signed a five-year agreement with Exact Sciences Corp. (Nasdaq: EXAS) for collaboration in the growing field of epigenetics and molecular diagnostics.

New Study Shows MDxHealth, Inc.'s SelectMDx Test Is Cost-Effective For Biopsy Selection

2017-04-10 devicespace
IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, April 10, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced BJU International published a study demonstrating that its SelectMDx(TM) for Prostate Cancer test can reduce overdiagnosis and overtreatment of men at risk of prostate cancer versus PSA testing alone, leading to a reduction in total cost per patient and a quality of life improvement.1

New Study Shows MDxHealth, Inc.'s SelectMDx Test Is Cost-Effective For Biopsy Selection

2017-04-10 devicespace
IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, April 10, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced BJU International published a study demonstrating that its SelectMDx(TM) for Prostate Cancer test can reduce overdiagnosis and overtreatment of men at risk of prostate cancer versus PSA testing alone, leading to a reduction in total cost per patient and a quality of life improvement.1

MDxHealth, Inc. Reports Financial Year 2016 Results

2017-02-23 devicespace
IRVINE, CA, and HERSTAL, BELGIUM - 7:00 AM, February 23, 2017 - MDxHealth SA (Euronext: MDXH.BR), or the "Company", today announced its financial results for the financial year ended December 31, 2016.

Liquid Biopsy Market by Cancer Type, Circulating Biomarkers, Product, End User - Forecast to 2021

2017-01-09 prnewswire
Growing Funding for Research on Liquid Biopsy and Technological Advancements to Boost the Growth of the Liquid Biopsy Market

MDxHealth, Inc. Provides Third Quarter 2016 Business Update

2016-11-02 devicespace
Herstal, Belgium, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Revenue for the first nine months up 84% to $22 million

5
shares
Ovarian Cancer Diagnostic Tests Market 2016 Pipeline Assessment

2016-10-03 prnewswire
ReportsnReports.com adds "Ovarian Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016" market research report providing comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Ovarian Cancer Diagnostic Tests pipeline products.

Liquid Biopsy Market: Global Industry Analysis and Opportunity Assessment 2016-2026

2016-09-28 prnewswire
NEW YORK, Sept. 28, 2016 /PRNewswire/ -- Report Synopsis This report by Future Market Insights (FMI) examines the 'Liquid Biopsy Market' for the period 2016–2026. The primary objective of the report is to offer updates and information related to market opportunities in the global liquid biopsy market. Report Description The global liquid biopsy market report begins by defining liquid biopsy and various types of markers used in liquid biopsy.

MDxHealth launches liquid biopsy test for prostate cancer in Europe

2016-09-17 seekingalpha
MDxHealth SA (OTC:MXDHF) launches a urine-based test, called SelectMDx, for prostate cancer in Europe. The test will be offered as a service through its laboratory facilities in Nijmegen, the Netherlands.

Liquid Biopsy Market Worth 1.66 Billion USD by 2021

2016-07-21 prnewswire
According to a new market research report " Liquid Biopsy Market Cancer Type (Lung, Breast, Colorectal, Prostate, Liver), Circulating Biomarkers (Circulating Tumor Cells, Circulating Tumor DNA), Product (Instruments, Software), End User (Reference Laboratory, Research Centers) - Forecast to 2021", published by MarketsandMarkets, The market is expected to reach USD 1.66 Billion by 2021 from USD 0.58 Billion in 2016, growing at a CAGR of 23.

Fintel IR - Find the Right Investors for Your Company, Instantly!

Fintel IR combines the comprehensive Fintel ownership database with machine learning to provide advanced tools to make investor outreach fast and easy. Learn more now!